BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Seite 3

User Base and Health Records:

• With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market.
• The platform’s scalability has the potential for exponential growth.

Quotes:

• Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation: “Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI.”
  
• Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd: “We welcome MRNA Scientific’s support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions.”

The handover ceremony took place at the Apollo Men’s Wellness Centre in Starhill, Kuala Lumpur on April 18^th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).

Photo:

Mr. Kenny Lai and Mr. CC Wong handing over the Letter of Offer to Mr. Andrew Teng and Mrs. Penny Attenbrough at Apollo Men’s Wellness Centre, witnessed by the CEO of BioNexus Gene Lab Corp., Mr. Sam Tan (centre)

About BioNexus Gene Lab Corporation:

BioNexus Gene Lab Corporation (NASDAQ: BGLC) is a global leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes.

For more information, visit BioNexus Gene Lab Corp.’s website: www.bionexusgenelab.com

About Ascension Innovation Sdn Bhd:

Ascension Innovation Sdn Bhd (AISB) is at the forefront of healthcare technology, driving innovation through its flagship platform, aiCMS.

For more information, visit Ascension Innovation Sdn Bhd’s website: www.aisb.io

¹ https://www.grandviewresearch.com/industry-analysis/digital-health-mar ...
² https://www.grandviewresearch.com/industry-analysis/artificial-intelli ...

---

For media inquiries, please contact:

Investor Relations
BioNexus Gene Lab Corporation
Email: [e-mail]

---

Disclaimer:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or projected. Forward-looking statements include, but are not limited to, statements regarding: